Introducing Key Performance Metrics for Assessing the Benefits and Harm of the Prostate Cancer Diagnostic Pathway

Traditional accuracy metrics no longer suffice for comparing diagnostic pathways for prostate cancer; new comparative performance metrics are needed that prioritize the overall benefit-to-harm ratio. Key performance metrics, such as biopsy efficiency, biopsy (grade) selectivity, and biopsy avoidance safety, enable meaningful patient-level comparisons across studies. Standardized benefit-to-harm metrics reporting enhances quality assurance, informs personalized diagnostics, and supports integration into clinical guidelines to improve the safety of prostate cancer diagnosis.